TY - JOUR
T1 - A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation
AU - Somwar, Romel
AU - Koterski, Sandra
AU - Sweeney, Gary
AU - Sciotti, Richard
AU - Djuric, Stevan
AU - Berg, Cathy
AU - Trevillyan, James
AU - Scherer, Philipp E.
AU - Rondinone, Christina M.
AU - Klip, Amira
PY - 2002/12/27
Y1 - 2002/12/27
N2 - Participation of p38 mitogen-activated protein kinase (p38) in insulin-induced glucose uptake was suggested using pyridinylimidazole p38 inhibitors (e.g. SB203580). However, the role of p38 in insulin action remains controversial. We further test p38 participation in glucose uptake using a dominant-negative p38 mutant and two novel pharmacological p38 inhibitors related to but different from SB203580. We present the structures and activities of the azaazulene pharmacophores A291077 and A304000. p38 kinase activity was inhibited in vitro by A291077 and A304000 (IC50 = 0.6 and 4.7 μM). At higher concentrations A291077 but not A304000 inhibited JNK2α (IC50 = 3.5 μM). Pretreatment of 3T3-L1 adipocytes and L6 myotubes expressing GLUT4myc (L6-GLUT4myc myotubes) with A291077, A304000, SB202190, or SB203580 reduced insulin-stimulated glucose uptake by 50-60%, whereas chemical analogues inert toward p38 were ineffective. Expression of an inducible, dominant-negative p38 mutant in 3T3-L1 adipocytes reduced insulin-stimulated glucose uptake. GLUT4 translocation to the cell surface, immunodetected on plasma membrane lawns of 3T3-L1 adipocytes or on intact L6-GLUT4myc myotubes, was not altered by chemical or molecular inhibition of p38. We propose that p38 contributes to enhancing GLUT4 activity, thereby increasing glucose uptake. In addition, the azaazulene class of inhibitors described will be useful to decipher cellular actions of p38 and JNK.
AB - Participation of p38 mitogen-activated protein kinase (p38) in insulin-induced glucose uptake was suggested using pyridinylimidazole p38 inhibitors (e.g. SB203580). However, the role of p38 in insulin action remains controversial. We further test p38 participation in glucose uptake using a dominant-negative p38 mutant and two novel pharmacological p38 inhibitors related to but different from SB203580. We present the structures and activities of the azaazulene pharmacophores A291077 and A304000. p38 kinase activity was inhibited in vitro by A291077 and A304000 (IC50 = 0.6 and 4.7 μM). At higher concentrations A291077 but not A304000 inhibited JNK2α (IC50 = 3.5 μM). Pretreatment of 3T3-L1 adipocytes and L6 myotubes expressing GLUT4myc (L6-GLUT4myc myotubes) with A291077, A304000, SB202190, or SB203580 reduced insulin-stimulated glucose uptake by 50-60%, whereas chemical analogues inert toward p38 were ineffective. Expression of an inducible, dominant-negative p38 mutant in 3T3-L1 adipocytes reduced insulin-stimulated glucose uptake. GLUT4 translocation to the cell surface, immunodetected on plasma membrane lawns of 3T3-L1 adipocytes or on intact L6-GLUT4myc myotubes, was not altered by chemical or molecular inhibition of p38. We propose that p38 contributes to enhancing GLUT4 activity, thereby increasing glucose uptake. In addition, the azaazulene class of inhibitors described will be useful to decipher cellular actions of p38 and JNK.
UR - http://www.scopus.com/inward/record.url?scp=0347721775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0347721775&partnerID=8YFLogxK
U2 - 10.1074/jbc.M205277200
DO - 10.1074/jbc.M205277200
M3 - Article
C2 - 12393894
AN - SCOPUS:0347721775
SN - 0021-9258
VL - 277
SP - 50386
EP - 50395
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 52
ER -